You just read:

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy (OBI-888).

News provided by

OBI Pharma, Inc.

17 Jan, 2018, 10:00 GMT